

DAFTAR PUSTAKA

1. Kidney Disease Improving Global Outcomes. Clinical practice guideline for evaluation and management of chronic disease. *Kidney Int Suppl.* 2023;(July).
2. Komaba H, Fukagawa M. FGF23-parathyroid interaction: Implications in chronic kidney disease. *Kidney Int.* 2010;77(4):292-298. doi:10.1038/ki.2009.466.
3. Fourtounas C. Phosphorus metabolism in chronic kidney disease. *Hippokratia.* 2011;15(SUPPL. 1):50-52.
4. Worung IM, Lestari AAW, Kandarini Y, Wande IN, Wirawati IAP, Mahartini NN. Correlation between serum levels of fibroblast growth factor-23 (FGF-23) and parathyroid hormone levels in predialysis chronic kidney disease (PGK) patients at sanglah general hospital, Bali, Indonesia. *Bali Med J.* 2021;10(2):830-834. doi:10.15562/bmj.v10i2.2527.
5. Rottembourg J, Urenã-Torres P, Toledano D, et al. Factors associated with parathyroid hormone control in haemodialysis patients with secondary hyperparathyroidism treated with cinacalcet in real-world clinical practice: Mimosa study. *Clin Kidney J.* 2019;12(6):871-879. doi:10.1093/ckj/sfz021.
6. Diniz H, Frazão JM. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder. *Nefrologia.* 2013;33(6):835-844. doi:10.3265/Nefrologia.pre2013.Jul.12091.
7. Quarles LD. Fibroblast growth factor 23 and α -Klotho co-dependent and independent functions. *Curr Opin Nephrol Hypertens.* 2019;28(1):16-25. doi:10.1097/MNH.0000000000000467.
8. González-Casaus ML, Gonzalez-Parra E, Fernandez-Calle P, Buño-Soto A. FGF23: From academic nephrology to personalized patients' care. *Nefrologia.* 2021; 41 (3): 276 - 283. doi: 10.1016/j. nefroe.2021.08.004.

9. Mace ML, Gravesen E, Hofman-Bang J, Olgaard K, Lewin E. Key role of the kidney in the regulation of fibroblast growth factor 23. *Kidney Int.* 2015;88(6):1304-1313. doi:10.1038/ki.2015.231.
10. Russo D, Battaglia Y. Clinical Significance of FGF-23 in Patients with PGK. *IntJ Nephrol.* 2011;2011:1-5. doi:10.4061/2011/364890.
11. Kidney C, Patients d. Correlation of serum fibroblast growth factor-23 levels and calcium-phosphate products levels in chronic kidney disease patients disusun dan diajukan oleh : 2022;1.
12. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of Renal Disease. *Perm J.* 2016;20(3):78-83. doi:10.7812/TPP/15-127.
13. Dias RSC, Brito DJ de A, Dos Santos EM, et al. Correlation between parathyroid hormone levels with urinary magnesium excretion in patients with non-dialysis dependent chronic kidney disease. *Int J Nephrol RenovascDis.* 2020;13:341-348. doi:10.2147/IJNRD.S282106.
14. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus kalsitriol in the treatment of secondary hyperparathyroidism. *Kidney Int.* 2003;63(4):1483-1490. doi:10.1046/j.1523-1755.2003.00878.x.
15. Caligara F, Giangrande A, Allaria P, Castiglioni A. The HPT-calcium relationship curve in secondary hyperparathyroidism, an index of sensitivity and suppressibility of parathyroid glands. *Nephrol Dial Transplant.* 1996;11(SUPPL. 3):136-141. doi:10.1093/ndt/11.suppl3.136.
16. Saliba W, El-Haddad B. Secondary hyperparathyroidism: Pathophysiology and treatment. *J Am Board Fam Med.* 2009;22 (5) : 574-581. doi:10.3122/jabfm.2009.05.090026.
17. Xu Y, Evans M, Carrero JJ, Soro M, Barany P. Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidneydisease. *Clin Kidney J.* 2021;14 (10) : 2213-2220. Doi : 10.1093/ckj/sfab006.
18. Ortiz A, Portoles J, et al. Clinical Characteristics and Management of Patients with Secondary Hyperparathyroidism Undergoing Hemodialysis: AFeasibility Analysis of Electronic Health Records Using Natural

- Language Processing. *Kidney Dis.* 2023; 9 (3) :187-196. doi: 10.1159/000528784.
19. Goodman WG, Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: Lessons from molecular genetics. *Kidney Int.* 2008;74(3):276-288. doi:10.1038/sj.ki.5002287.
 20. Nagaraju SP, Shenoy SV, Gupta A. Frailty in end stage renal disease: Current perspectives. *Nefrologia.* 2022; 42 (5): 531-539. doi: 10.1016/j.nefro. 2021.05.008
 21. Chamney M, Podham M, Anderson J. Chronic kidney disease (PGK). *Chronic Care Nurs A Framew Pract.* Published online 2016 : 240-257. Doi :10.1007/978-3-642-12483-9_9.